MeSH D018352 - coronavirus infections
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D003333:Coronaviridae infections
0 Companies
0 Drugs
Success rate
D018352:
Coronavirus infections
D000086382:Covid-19
D004753:Transmissible enteritis of turkeys
0 Companies
0 Drugs
Success rate
D005761:Transmissible gastroenteritis of swine
0 Companies
0 Drugs
Success rate
D016766:Feline infectious peritonitis
0 Companies
0 Drugs
Success rate
D045169:Severe acute respiratory syndrome
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Gilead Sciences | Remdesivir | Veklury | 2029-04-22 | 2020-10-22 | $2,180 M | Q4/23-Q3/24 |
Clinical Trials
Historical Success Rate
Phase 1
61%11/18
Phase 2
30%13/43
Phase 3
31%8/26
Approved: 4Overall Success rate: 6%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use